REGN-5715
- Generic Name
- REGN-5715
A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
Phase 3
Active, not recruiting
- Conditions
- Allergic Conjunctivitis
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT06602739
- Locations
- πΊπΈ
Andover Eye Associates, Andover, Massachusetts, United States
π¨π¦Kingston Health Sciences Centre, Kingston, Ontario, Canada
π¨π¦Clinique de Specialisee en Allergie de la Capitale, Quebec, Canada
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Phase 2
Completed
- Conditions
- Allergic RhinitisConjunctivitis
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 217
- Registration Number
- NCT05430919
- Locations
- π¨π¦
Inflamax Research Limited DBA Cliantha Research, Mississauga, Ontario, Canada
π¨π¦Kingston General Health Research Institute, Kingston, Ontario, Canada
π¨π¦Clinique Specialisee en Allergie de la Capitale, Quebec City, Quebec, Canada
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
Phase 3
Completed
- Conditions
- Allergic RhinitisConjunctivitis
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 353
- Registration Number
- NCT04709575
- Locations
- π©πͺ
Regeneron Study Site, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath